Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 715 of 767

Advanced search

🇺🇸Jun 14, 2023Industrydyne-tx.comTier 1 · Company source

Cookie Declaration - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🌍May 23, 2023Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Announces $54 Million Series C Financing

OnKure TherapeuticsOriginal source

🌍May 18, 2023Industrycytomx.comTier 1 · Company source

Designing Conditionally Activated Probody® Cytokines to Localize Antitumor Activity to Cancers

CytomX TherapeuticsOriginal source

🌍May 10, 2023Industrycerbios.swissTier 3 · Secondary coverage

HPAPI and ADC payload manufacturing capacity expansion

Cerbios-Pharma SAOriginal source

🇺🇸May 10, 2023Researchforesitecapital.comTier 2 · Direct publisher

Announcing XinThera’s Acquisition by Gilead Sciences

Foresite CapitalOriginal source

🌍May 9, 2023Industrymaxcyte.comTier 1 · Company source

maxcyte establishes new scientific advisory board comprised of globally recognized experts in cell engineering enabling technology

MaxCyteOriginal source

🌍May 8, 2023Industrymaxcyte.comTier 1 · Company source

maxcyte appoints douglas swirsky as chief financial officer

MaxCyteOriginal source

🌍May 1, 2023Industrymoleculetomarketpod.comTier 3 · Secondary coverage

Molecule to Market: Meet the lean, keen biotech

Portage BiotechOriginal source

🌍Apr 28, 2023Industrymoleculetomarketpod.comTier 3 · Secondary coverage

Molecule to Market: Why biotechs are feeling the bite

Portage BiotechOriginal source

🌍Apr 27, 2023Deviceschembio.comTier 3 · Secondary coverage

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc.Original source

🇺🇸Apr 27, 2023Industrydyne-tx.comTier 1 · Company source

our-commitment-video - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🌍Apr 26, 2023Industryperspective.comTier 1 · Company source

Board Testimonials — Perspective Group

Perspective TherapeuticsOriginal source

🌍Apr 25, 2023Mediaphillipsmedisize.comTier 3 · Secondary coverage

Top 5 Considerations for Medical Wearables

Phillips MedisizeOriginal source

🌍Apr 21, 2023Mediaphillipsmedisize.comTier 3 · Secondary coverage

Mastering the Challenges of Continuous Glucose Monitor Design

Phillips MedisizeOriginal source

🇫🇷Apr 12, 2023Industrypierre-fabre.comTier 1 · Company source

Pierre Fabre annonce l’acquisition de la marque MÊME

Pierre FabreOriginal source

🇺🇸Mar 28, 2023Industrydyne-tx.comTier 1 · Company source

Dyne Culture Video - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇰Mar 20, 2023Industrygenialcompliance.comTier 3 · Secondary coverage

Genial at ICHG 2023 - Genial

Genial Genetics (Pathozoom AI)Original source

🇺🇰Mar 9, 2023Industrygenialcompliance.comTier 3 · Secondary coverage

How the ISO 15189 standard is changing and what that means for you - Genial

Genial Genetics (Pathozoom AI)Original source

🌍Mar 7, 2023Industryperspective.comTier 1 · Company source

Perspective Group 2H22 Highlights — Perspective Group

Perspective TherapeuticsOriginal source

🌍Feb 25, 2023Mediaphillipsmedisize.comTier 3 · Secondary coverage

Optimize Medical Device Design with Magnesium Thixomolding

Phillips MedisizeOriginal source

🌍Feb 24, 2023Deviceschembio.comTier 3 · Secondary coverage

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

Chembio Diagnostics, Inc.Original source

🇺🇸Feb 24, 2023Industrydyne-tx.comTier 1 · Company source

Rare Disease Day 2023 - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇸Feb 14, 2023Researchforesitecapital.comTier 2 · Direct publisher

On-Site with Foresite: Meet Michael Rome

Foresite CapitalOriginal source

🌍Feb 9, 2023Mediaphillipsmedisize.comTier 3 · Secondary coverage

Metal Injection Molding Makes a Big Impact on Small Parts

Phillips MedisizeOriginal source

🇨🇦Jan 24, 2023Researchucalgary.caTier 2 · Direct publisher

Student group champions accessibility pilot project in lecture halls

University of CalgaryOriginal source

🇺🇰Jan 4, 2023Industrygenialcompliance.comTier 3 · Secondary coverage

First online iPassport User Group a great success - Genial

Genial Genetics (Pathozoom AI)Original source

🌍Dec 29, 2022Industryperspective.comTier 1 · Company source

Perspective shares BOD Insights and Successes — Perspective Group

Perspective TherapeuticsOriginal source

🇧🇪Dec 22, 2022Regulatoryfamhp.beTier 1 · Regulatory source

FAMHP reminds of need for customer declaration for buyers of category 1 or 2 chemicals

FAMHP (Belgium)Original source

🌍Dec 15, 2022Industryblueprintgenetics.comTier 1 · Company source

Our service hours during the holiday season

Blueprint Genetics (Quest Diagnostics)Original source

🌍Dec 15, 2022Industrycytomx.comTier 1 · Company source

Results of a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

CytomX TherapeuticsOriginal source

🇺🇸Dec 13, 2022Industrydyne-tx.comTier 1 · Company source

FORCE-for-Good-Service-Day-2022 - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🌍Dec 9, 2022Industryperspective.comTier 1 · Company source

Perspective shares CEO Insights and Successes — Perspective Group

Perspective TherapeuticsOriginal source

🌍Dec 6, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations

OnKure TherapeuticsOriginal source

🇺🇸Nov 29, 2022Industrydyne-tx.comTier 1 · Company source

DM1 Story - BillyDean - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇸Nov 23, 2022Researchcidrap.umn.eduTier 2 · Direct publisher

Remdesivir, steroids tied to better COVID hospital outcomes

CIDRAPOriginal source

🇺🇸Nov 23, 2022Industrydyne-tx.comTier 1 · Company source

DM1 Story - Joachim - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇸Nov 23, 2022Industrydyne-tx.comTier 1 · Company source

DM1 Story - Loraine - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇸Nov 23, 2022Industrydyne-tx.comTier 1 · Company source

DMD Story - Ravi - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🌍Nov 15, 2022Industrycytomx.comTier 1 · Company source

CX-801, Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in Tumors

CytomX TherapeuticsOriginal source

🇺🇸Nov 2, 2022CDMOnoramco.comTier 2 · Direct publisher

Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

NoramcoOriginal source

🌍Oct 27, 2022Industryq32bio.comTier 1 · Company source

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Q32 BioOriginal source

🇬🇧Oct 27, 2022Researchhdruk.ac.ukTier 2 · Direct publisher

Tim Ferris, Jenny Harries and Mauricio Barreto confirmed to join HDR UK’s Annual Scientific Conference

Health Data Research UKOriginal source

🌍Sep 20, 2022Industryq32bio.comTier 1 · Company source

Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition

Q32 BioOriginal source

🇺🇸Sep 17, 2022Researchforesitecapital.comTier 2 · Direct publisher

In Memoriam – Stephen Kaldor

Foresite CapitalOriginal source

🇺🇸Sep 15, 2022Industrydyne-tx.comTier 1 · Company source

joachim and tim

Dyne TherapeuticsOriginal source

🇺🇸Sep 14, 2022Industrynurabio.comTier 1 · Company source

Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON Nura Bio™

Nura BioOriginal source

🇺🇸Sep 14, 2022Industrynurabio.comTier 1 · Company source

Marc Freeman wins first annual Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative HealingNura Bio™

Nura BioOriginal source

🌍Sep 7, 2022Industrycytomx.comTier 1 · Company source

Tailoring the Selection of Target, Payload, and Tumor Type to Maximize the Therapeutic Index of Conditionally Activated ADCs

CytomX TherapeuticsOriginal source

🇺🇸Sep 7, 2022Industrydyne-tx.comTier 1 · Company source

diana and jordan 2022

Dyne TherapeuticsOriginal source

🇺🇸Sep 6, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics to Present at 3rd Annual Jefferies Asia Forum | Sirnaomics

SirnaomicsOriginal source

🇺🇸Aug 31, 2022Industrydyne-tx.comTier 1 · Company source

rdd2022

Dyne TherapeuticsOriginal source

🇺🇸Aug 26, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

SirnaomicsOriginal source

🌍Aug 25, 2022Industryomniab.comTier 1 · Company source

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

OmniAbOriginal source

🇺🇰Aug 25, 2022Industrygenialcompliance.comTier 3 · Secondary coverage

Most common risks to accreditation during inspection - Genial

Genial Genetics (Pathozoom AI)Original source

🇺🇸Aug 23, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics' 2022 interim results presentation will be held on 31 August 2022 | Sirnaomics

SirnaomicsOriginal source

🇺🇸Aug 19, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics becoming a Constituent of Hang Seng Family of Indexes | Sirnaomics

SirnaomicsOriginal source

🌍Aug 15, 2022Industryq32bio.comTier 1 · Company source

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Q32 BioOriginal source

🇺🇸Aug 15, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics | Sirnaomics

SirnaomicsOriginal source

🌍Aug 3, 2022Mediaphillipsmedisize.comTier 3 · Secondary coverage

Alzheimer’s Disease: Navigating the Challenging Journey to a Cure

Phillips MedisizeOriginal source

🇺🇸Jul 22, 2022Industrydyne-tx.comTier 1 · Company source

world fshd day 2022

Dyne TherapeuticsOriginal source